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Cardiovascular disease and uraemia
Uraemic syndrome can be defined as the combination of all
clinical problems that occur when kidney function is pro-
gressively declining. Those are to a large extent attributed
to the retention of compounds, in the body, that under nor-
mal conditions would be removed from the blood stream
by the healthy kidneys; they are therefore named uraemic
retention solutes. As long as these molecules exert biologi-
cal/biochemical impact, they are called uraemic toxins, and
in that case they contribute to the uraemic syndrome. Some
uraemic retention products may be useful markers of solute
removal and retention, even if they are not toxic.
A highly bothersome complication of chronic kidney
disease (CKD) is the concomitant cardiovascular damage.
Although first recognized more than three decades ago [1],
the true dimensions of the problem became clear only some
10 years ago [2]. The general impact on public health has
long been underestimated, but is now accepted to be at
least as important as that of diabetic cardiovascular damage
[3].
Whereas cardiovascular disease was originally consid-
ered relevant especially in the dialysed population [2], and
hence seemed to affect only a minor fraction of the general
population, later on it became clear that increased morbid-
ity and mortality were present at much earlier stages of
CKD, long before the development of the need for dialysis.
There is now a general consensus that cardiovascular risk
increases from a glomerular filtration rate (GFR) of 60 mL/
min/1.73 m2 on [3], which corresponds to a loss of
kidney function of only 50%. According to some studies,
risk becomes significant even earlier, from a GFR of
90 mL/min/1.73 m2 on [4]. Consequently, the group at risk
extends over a large proportion of the general population,
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allegedly from 7 to 30% of all subjects. Since it is conceiv-
able that uraemic retention starts from the moment kidney
function decreases, the solutes that we will describe below
start to play a role already at these early stages of kidney
failure.
Of note, the quality of vessels is to a large extent different
in the uraemic population, as compared to the population
with normal kidney function, irrespective of stenotic or
thrombotic lesions.
The arterial system undergoes a specific remodelling
process, characterized by increased wall stiffness in par-
allel with the decline in renal function [5], resulting in
a decreased dampening of pressure and flow oscillations
and a progressive disturbance of the normal ventricular–
vascular coupling. The ejection of the same blood volume
in a stiffer central arterial system generates a high-pressure
wave, which propagates faster towards the periphery (in-
creased pulse wave velocity) and whose reflection comes
back earlier during the cardiac cycle (wave reflection). The
resulting mismatch between the higher systolic workload
and decreased diastolic perfusion leads to a lower coronary
reserve, irrespective of stenotic or thrombotic lesions.
To some extent, arterial stiffness can be attributed to
medial wall calcification or ‘elastocalcinosis’, a specific
feature of the overall increased propensity of patients with
kidney disease to develop calcifications.
Although patients suffering from CKD are frequently af-
fected by a number of other conditions and/or comorbidities
that enhance cardiovascular risk, such as hypertension, in-
sulin resistance, fluid overload, anaemia, diabetes mellitus
and dyslipidaemia, the weight of these factors per se has
been shown to be insufficient to explain the entire uraemic
cardiovascular problem; therefore, it has been suggested
that factors specific to CKD such as the uraemic milieu
must play a central role [6].
One of these factors is (micro) albuminuria, although
this might be considered as a marker of endothelial dam-
age rather than a real cause. Another likely and more direct
explanation is the role played by uraemic retention solutes
[7]. Several of these compounds have been shown to have
the capacity to cause cardiovascular damage [7], and this
property is conceivably intensified by their increased con-
centration following the incapacity of the kidneys to excrete
them.
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In this article, we will first review current knowledge on
uraemic toxins with a potential cardiovascular impact; we
will then give an example of how this knowledge can be
translated into therapeutic measures improving outcome in
the population with CKD. Finally, we will consider options
for the future and we will try to outline strategies showing
how this knowledge can be extended and applied for a
further improvement of the clinical condition of the affected
patients.
Potential culprits: baseline in vitro and
epidemiological data
Several uraemic retention solutes have been associated
with cardiovascular damage [7]. Especially during the last
decade, knowledge about compounds with the potential
to affect the cardiovascular system has been continuously
growing [7]. Due to space limitations, in what follows we
will give a few examples, especially on compounds regard-
ingwhich our current knowledge has recently been changed
fundamentally. An extensive overview per uraemic solute
of effects with the potential to damage heart or vessels
and of epidemiological studies linking these compounds to
outcome is given in Table 1.
Small water-soluble compounds
• Guanidines. Guanidines are, in a comparable way to
urea, small and water-soluble products of protein break-
down. Historically, since long they have been considered
as neurotoxins, but more recently, they were also linked to
vascular damage, as it was demonstrated that several of the
solutes of this group activated leukocyte function [8]. In
addition, guanidines were also shown to modify albumin
structure, in such a way as to decrease the protein binding
of homocysteine (Hcy) [9], hence stimulating the release
of free, active Hcy and enhancing cardiovascular damaging
potential.
The concentration of another guanidine, asymmetric
dimethylarginine (ADMA), has been related to several
parameters of vascular outcome [10,11]. Symmetric
dimethylarginine (SDMA), a structural variant of ADMA,
was considered inert until recently, but has nowequally been
suggested to be related to vascular damage by inhibition of
inducible nitric oxide synthase [12].
In spite of being small and water soluble, guanidines
nevertheless show a kinetic behaviour that diverges from
that of urea [13,14].
• Phosphate. Phosphate is considered as one of the ma-
jor uraemic toxins involved in the early phases of vascular
calcification. More importantly, in contrast to its previ-
ously believed passive role in chemical complexation with
calcium due to supersaturation of plasma, recent evidence
indicates that phosphate may induce direct cellular effects.
This involves the activation of genes (Cbfa-1) that cause
vascular smooth cell transdifferentiation into osteoblast-
like cells [15] capable of producing hydroxyappatite crys-
tals. Therefore, arterial calcification is currently considered
an active regulated process, similar to bone formation. Al-
though large epidemiological studies have shown an inde-
pendent relationship between phosphate concentrations and
the outcome [16], the net effect also depends on levels of
calcium and the integrity of counterregulatorymechanisms.
Of potential clinical importance are systemic calcification
inhibitors, such as fetuin-A, as well as local inhibitors such
as matrix-GLA protein (vitamin K dependent, inhibited by
warfarin), pyrophosphate (water soluble and eliminated by
dialysis) and osteoprotegerin. Finally, the calcification pro-
cess is also influenced by the complex interaction of distur-
bances in phosphorus handling and calcium balance with
bone buffering capacity, level of parathyroid activity and
vitamin D status.
Protein-bound molecules
• Homocysteine. Homocysteine (Hcy), a sulphur-
containing amino acid, is produced by the demethylation
of dietary methionine. Moderate hyperhomocysteinaemia
is an independent risk factor for cardiovascular disease in
the general population [17]. Patients with chronic kidney
failure have serumHcy levels two to fourfold above normal.
Hcy increases the proliferation of vascular smooth muscle
cells, one of the most prominent hallmarks of atheroscle-
rosis [18]. Moderate hyperhomocysteinaemia may induce
endothelial dysfunction and generate oxidative oxygen
species [19]. Hcy-induced superoxide anion generation is
responsible for NF-κB activation and subsequent mono-
cyte chemoattractant protein-1 (MCP-1) expression in
macrophages [20] inducing inflammatory responses. The
administration of excessive quantities of the Hcy precursor
methionine to rats induces atherosclerosis-like alterations
in the aorta [21]. Hcy also disrupts several anticoagulant
functions in the vessel wall, which results in enhanced
thrombogenicity [22]. Studies of the potential of folic acid
or 5-methyltetrahydrophosphate (MTHF) to decrease Hcy
levels emanated in contradictory results. Touam et al. were
able to reduce total Hcy to normal in ∼50% of the studied
population, by administration of folinic acid, a precursor of
MTHF [23]. The study of van Guldener et al., on the other
hand, showed that even when it was possible to decrease
Hcy levels therapeutically, carotid artery stiffness was not
altered [24].
• Indoles. Indoles are a group of protein-bound com-
pounds, which are generated by chemical transformation
processes such as conjugation. Indoxyl sulphate, the most
abundant indolic compound in uraemia, has been linked
to endothelial damage, inhibition of endothelial regener-
ation and repair and endothelial free-radical production
[25,26].
• P-cresylsulphate. Although most of the pioneering re-
search on phenolic compounds has been focused on the
concentration and the toxicity of the mother compound
p-cresol, later work revealed that genuine p-cresol was
present at very low concentrations in patients with renal
failure and most of the p-cresol, generated by the intesti-
nal flora, was conjugated to p-cresylsulphate in the intesti-
nal wall and p-cresylglucuronide in the liver [27,28]. Both
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Table 1. Uraemic retention solutes with cardiovascular damaging potential
Vascular damaging effect Clinical correlate
Small water-soluble compounds
ADMA Vasoconstriction Vascular outcome
Inhibition iNOS
Guanidino compounds Inflammation
Phosphate Calcification Outcome
SDMA Inhibition iNOS
Leukocyte activation
Protein-bound moleculesa
Homocysteine Leukocyte activation Outcomeb
Smooth muscle cell proliferation
Endothelial function
Indoles Endothelial function
P-cresylsulphate Leukocyte activation Outcomec
Hospitalizationc
Uraemic symptomsc
Phenylacetic acid Inhibition iNOS
Middle molecules
AGEs Inflammation
AOPPs Inflammation
Angiotensin A Vasoconstriction
β2-microglobulin Monocyte migration
d Outcome
Cytokine secretiond
BFGF Smooth muscle cell proliferation
Complement factor D Activation alternative complement pathway
Cytokines Inflammatione Outcome
Endothelial function
Thrombocyte activation
Smooth muscle cell proliferation
Dinucleotide polyphosphates Vasoconstriction
Smooth muscle cell proliferation
Leukocyte activation
Endothelin Vasoconstriction
Arterial stiffness
Oxidative stress
Inflammation
Insulin resistance
Hyaluronic acid Expression VCAM-1 Outcome
Expression MCP-1
Leptin Inflammation CRP
Endothelial function Nutritional status
Thrombocyte activation
Neuropeptide-Y Vasoconstriction Cardiovascular complications
Parathyroid hormone Inflammation Outcome
Vessel-wall calcification
Resistin Inflammation
Insulin resistance
ADMA: asymmetric dimethylarginine; iNOS: inducible nitric oxide synthase (endothelial protection); SDMA: symmetric dimethylarginine; AGEs:
advanced glycation end products; AOPPs: advanced oxidation protein products; BFGF: basic fibroblast growth factor; VCAM-1: vascular cell adhesion
molecule-1; MCP-1: monocyte chemoattractant protein-1; CRP: C-reactive protein.
aProtein-bound middle molecules will be mentioned in the section devoted to middle molecules and will be marked in italics.
bIf corrected for nutritional status.
cP-cresylsulphate measured as p-cresol after acidic hydrolysis.
dOnly AGE-modified β2-microglobulin AGE-modified.
eOnly for pro-inflammatory cytokines.
conjugates are characterized by a strong protein binding.
The reason for the incorrect previous emphasis on p-cresol
was due to the fact that most determination methods were
based on deproteinization by acidification, causing disinte-
gration of the conjugates by hydrolysis. Application of de-
proteinization methods without acidification revealed the
presence of the conjugate p-cresylsulphate [27]. Further
studies indicated that the biochemical impact of the mother
compound p-cresol is not necessarily the same as that of the
conjugate. Whereas p-cresol suppresses activity of leuko-
cytes, especially after their activation, p-cresylsulphate
essentially appeared to be linked to baseline leukocyte ac-
tivation [29]. Nevertheless, since there is probably a cor-
relation between former p-cresol estimations and current
p-cresylsulphate measurements, previously held conclu-
sions regarding p-cresol about protein binding and rela-
tionship with clinical outcome parameters [30–32] are very
likely still valid for the conjugates as well.
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• Phenylacetic acid. Phenylacetic acid (PAA) is a degra-
dation product of the amino acid phenylalanine. Plasma
concentrations of PAA in stage 5 CKD patients strongly
exceeded those in healthy controls. PAA was identified as
an inhibitor of Ca2+-ATPase activity [33] and was shown
to inhibit expression of inducible nitric oxide synthase
(iNOS), a protective enzyme of the endothelium [34]. Con-
sequently, inhibition of NO production might reinforce vas-
cular damage. Recently, PAA concentrations in CKD stage
5 patients were shown to correlate with arterial properties
corresponding to vascular damage [35].
Middle molecules
• Advanced glycation end products (AGEs) and advanced
oxidation protein products (AOPPs). AGEs and AOPPs
are generated by oxidative processes and are often incorpo-
rated into larger molecules and peptide/protein structures.
Although the basic elements composing AGEs and AOPPs
do not necessarily have a high molecular weight, once they
are linked to peptidic or protein structures, their molecular
weight becomes important enough to hamper their removal
by standard dialysis strategies [36].
AGEs and AOPPs activate inflammatory processes,
which are involved in vascular damage [37,38]. Recent data
suggest that AOPP concentrations measured with classical
methods [39] are biased by a background noise created by
triglycerides, coagulation factors and very likely other as
yet unidentified factors [40,41].
• Angiotensin A. Next to genuine angiotensin, structural
variants, such as angiotensin A, characterized by the de-
carbolization of the asparagine molecule in the angiotensin
peptide, have been described [42]. These structural variants
also have vasoactive properties, albeit not necessarily to the
same extent as genuine angiotensin II; the concentration of
angiotensin A is relatively increased in CKD as compared
to subjects with normal kidney function. It is conceivable
that other variants of angiotensin might exist, be retained
in kidney disease and play a pathophysiological role in vas-
cular dysfunction as well.
• Cytokines. Related to the strong association among
atherosclerosis, malnutrition and inflammation [43], pro-
inflammatory cytokine system activity is elevated in CKD
[44]. Concentration of pro-inflammatory cytokines is cor-
related to adjusted mortality of haemodialysis patients [44].
• Dinucleotide polyphosphates. Dinucleoside polyphos-
phates are a group of substances involved in the regulation
of vascular tone, as well as in the proliferation of vascular
smooth muscle cells [45] and mesangial cells [46]. Specific
members of this group, diadenosine polyphosphates, were
detected in hepatocytes, human plasma [47] and platelets.
In addition, concentrations of diadenosine polyphosphates
were increased in platelets from haemodialysis patients
[48]. Recently, uridine adenosine tetraphosphate (Up4A)
was isolated and identified as a novel endothelium-derived
vasoconstrictive factor. Its vasoconstrictive effects, plasma
concentration and release upon endothelial stimulation
strongly suggest that Up4A has a functional vasoregula-
tory role [49].
• Resistin. Resistin levels are higher in dialyzed than in
non-dialyzed CKD patients [50], and in the non-dialyzed,
concentrations correlate inversely with GFR [51]. In CKD,
circulating levels are also strongly associated with inflam-
matory biomarkers [52], but not with insulin resistance
[52,53], although resistin administration to laboratory an-
imals impairs glucose tolerance and the action of insulin
[54].
Summary
Many of the compounds accumulated in CKD have the ca-
pacity to interfere with themetabolic systems in the body so
as to create cardiovascular damage (Table 1). If we trans-
late this information into physicochemical characteristics
impacting on removal by dialysis, as of today still the most
important method to eliminate these molecules and their
effects, it is clear that the majority of these compounds are
so-called molecules that are difficult to remove by dialy-
sis, such as middle molecules or protein-bound molecules
(Table 1). Such compounds are not or barely removed by
standard dialysis strategies and, to eliminate them more ef-
ficiently, one has to utilize more complex methods such as
high-flux dialysis or convective strategies, and/or one has
to modify standard conditions, e.g. by prolonging dialysis
time. Even guanidines, in spite of being small andwater sol-
uble, have markedly different kinetic characteristics from
our current marker urea.
Hence, it should be realized that in uraemic retention in
general, as well as in uraemic retention related to cardio-
vascular risk, there is more than urea alone. In addition, in
uraemic toxin removal, it may also be useful to pursue more
than urea removal alone.
Translation of knowledge into clinical outcome
studies
Inwhat follows,wewill first give an example of howknowl-
edge collected from in vitro studies and epidemiological
assessments, such as the data summarized in the section
above and in Table 1, has ultimately led to information per-
mitting an improvement of the therapeutic approach and
condition of patients. We will then consider which further
strategies should be considered for the future, in an attempt
to influence various aspects of uraemic retention.
Current status—updated example
As mentioned above, a host of uraemic solutes with the
potential to damage heart and vessels, are larger so-called
middle molecules that are not removed by standard dialysis
using dialyzers with small pores (low flux), but only via
open high-flux membranes with larger pores [55,56].
In the past, several observational or epidemiological stud-
ies demonstrated that high-flux membranes were related to
a better patient outcome [55,57,58].
The HEMO study, a four-armed study not only compar-
ing low-flux to high-flux haemodialysis, but also standard
dialysis adequacy to high adequacy as defined by different
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Table 2. Comparison of the HEMO and MPO studies
HEMO MPO
Study arms 4 2
Randomization Stratified by centre, Stratified by centre and
diabetes status and age serum albumin
Follow-up 1–5 years 3–7.5 years
Study sites USA nine European countries
Type of patients Prevalent Incident
Albumin status ≥2.6 g/dL Large majority (75%)
≤4.0 g/dL
Treatment time ≤4.5 h ≥3 h
Dialyzer reuse Yes No
Definition of Including ‘medium flux’ Strictly ‘high flux’
high flux
levels of Kt/Vurea, was the first controlled study evaluat-
ing the impact of dialyzer pore size on patient outcome
[59]. At primary analysis, no difference in overall survival
could be found between low-flux and high-flux haemodial-
yses. Such a difference in favour of high-flux haemodialysis
was present, however, at several secondary analyses while
considering (1) cardiac mortality or cardiac mortality plus
hospitalization for cardiac reasons for the entire population
[59]; (2) overall outcome in those patients who had been en-
rolled into the study after a time on dialysis that was longer
than the median for the entire group (>3.7 years) [60] and
(3) cerebrovascular mortality [61]. In addition, irrespective
of the membrane type, outcome was inversely correlated
to mean cumulative pre-dialysis β2-microglobulin concen-
tration [62]. In the second wave of European Best Prac-
tice Guidelines for haemodialysis, which were published
in May 2007, all these data together led to the recommen-
dation to preferably use high-flux dialyzer membranes for
haemodialysis treatment [63].
The Membrane Permeability Outcome (MPO) study is
a European study with some striking points of difference
with the HEMO study (Table 2) [64]. The MPO study was
relatively well powered, with a targeted sample of 660 pa-
tients (exceeded at the end of enrolment by 78 additional
patients) for only two study arms. Randomization was per-
formed separately for the two albumin strata. In the MPO
study, the threshold pore size defining high-flux mem-
branes was larger than in the HEMO study, as exempli-
fied by a markedly higher ultrafiltration coefficient and β2-
microglobulin clearance. The length of the follow-up was
considerably longer than that in the HEMO study, with fo-
cus on incident patients startingwith dialysis under a poorer
clinical condition upon enrolment (serum albumin ≤4.0
g/dL for the large majority of patients). Although the study
was originally designed only for such hypoalbuminaemic
patients, the protocol was amended after 11 months due to
too slow patient inclusion into the study, and from then on
normoalbuminaemic patients were also enrolled. At the end
of the study, however, 76.2% of patients under evaluation
appeared to have been still hypoalbuminaemic, according
to the study definitions.
As compared to low flux, outcome was significantly
better in the 492 hypoalbumaemic patients treated with
high-flux membranes (P = 0.032) (presentation by F. Lo-
catelli at the ERA–EDTA meeting in Barcelona, 2007).
There was also a survival advantage for high flux in the
patients with diabetes mellitus, either when analysing the
overall group (P = 0.0385) or the group with hypoalbu-
minaemia (P= 0.006). The latter data are strikingly parallel
with the findings of a secondary analysis of the 4D study,
originally designed to evaluate the impact of a statin on sur-
vival of diabetic dialysis patients, since here also a survival
advantage for high-fluxmembranes was demonstrated [65].
All in all, the MPO study shows a survival advantage
for high flux in hypoalbuminaemic and diabetic subjects,
i.e. the subgroups on dialysis with poor general condition
and outcome prognosis. Conceivably, it is easier to reach
sufficient statistical power to demonstrate an outcome dif-
ference in such populations with less brilliant prospects.
Of note, both hypoalbuminaemia and diabetes are frequent
conditions among dialysis patients, and with a continuously
growing incidence.
In a broader perspective, these data show how increasing
knowledge of uraemic toxins with middle molecular weight
and their potential to induce vascular damage has led to
an increasing use of membranes with larger pore size and
ultimately to controlled studies showing a survival advan-
tage for such membranes.
Is this the ultimate endpoint or are more questions aris-
ing ahead of the knowledge that we have already acquired?
Large molecules and even protein-bound molecules might
be more efficiently removed by applying convective strate-
gies. In that case, plasma water is ultrafiltered from the
body and replaced by equivoluminous amounts of sterile
saline. Although this substitution was originally admin-
istered as pharmacologically prepared solutions in bags,
hence limiting the administered amount essentially due to
cost limitations, more recently it has become possible to
administer substitution fluid as ultrapure dialysate in much
more substantial amounts, due to improvements in dialysis
water preparation strategies.
Since in the HEMO study, survival was inversely linked
to β2-microglobulin concentrations [62], it is conceivable
that further increasing middle molecule removal by adding
convection to diffusive dialysis will lead to a further out-
come benefit. A number of observational studies point in
this direction [66–68]. At the moment, several large con-
trolled multicentre studies are being conducted to test this
hypothesis [69–71].
Strategies for the future
It is clear from the previous sections that on one hand, our
knowledge about the factors involved in uraemic syndrome
and their responsibility in provoking cardiovascular dam-
age is incomplete, but on the other hand, it is also clear that
gaining knowledge in this area may be of help for develop-
ing and testing new preventive or therapeutic methods with
clinical benefit.
In what follows we describe an approach for the future
that could be of help in finding new therapeutic strate-
gies to improve quality of life and survival of uraemic
patients. This strategy is summarized as a flowchart in
Figure 1.
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Fig. 1. Suggested approach for the future, helping to find new therapeutic strategies to improve quality of life and survival of uraemic patients.
In view of our incomplete knowledge of the toxic effects
of uraemic solutes, in vitro efforts should be continued
to identify as yet unknown toxic effects, on one hand by
continuing the study of already known solutes and on
the other by the evaluation of newly detected toxins. Ap-
proaches that might be helpful for the detection of new
toxins are recent acquisitions in the fields of proteomics,
metabonomics and/or genomics. All these strategies make
use of comparison of well-defined patient groups (e.g.
those with previous cardiovascular events and those with-
out; those with and without malnutrition), which are as-
sessed by highly efficient analytical and biostatistical tools
allowing to detect discriminators between patient groups,
which are present in one group and absent in another.
After identification of the structure of those compounds,
they then can be submitted to further in vitro analysis.
Our research and understanding can also benefit
from the application or integration of advances in other
medical areas, such as cardiovascular medicine and
endocrinology (hormonal and bone diseases), as well as
from the understanding of rare monogenic disorders that
show similarities with metabolic or pathophysiological
disturbances observed in kidney disease. Examples are the
relationship between osteoporosis and vascular calcifica-
tion in non-CKD patients, and the Keutel syndrome, an
autosomal recessive disorder resulting in a non-functional
matrix-GLA protein and characterized by severe vascular
media calcification [72].
In vitro analysis, be it on well-known or newly detected
compounds, is best done in a standardized manner so that
results from different laboratories can be compared and
allow classification if several potential culprits emanate
from a series of analyses. Recommendations for such a
standardized approach have been formulated recently [73].
Once potentially responsible compounds have been
recognized in vitro, their in vivo impact can be stud-
ied clinically in epidemiological studies, evaluating their
relationship with outcome and/or relevant complications/
comorbidities.
In vitro analysis in combination with epidemiological
studies should enable classification of potential culprits,
in order to develop a sequence of importance for further
analysis of involved pathways, which in turn can then lead
towards new therapeutic strategies.
In particular, the compounds with the strongest impact
should be submitted to evaluation of the involved metabolic
pathways, which should allow us to develop pharmaco-
logical therapies to counteract these pathways. These ap-
proaches can then be applied not only at the latest stages
of CKD, but also during earlier non-dialytic stages. This
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Fig. 2. The presently known uraemic retention solutes with a negative impact on the major cell types involved in the development of cardiovascular
disease (adapted and extended from [7]).
extends the group of interest up to 5 to 10% of the gen-
eral population, which is much more than the ± 0.1% of
people who are candidates for renal replacement therapy.
The group of interest also comprises renal transplant re-
cipients who almost always suffer from a certain degree
of renal failure. It could be argued that such preventive
pharmacologic measures already exist, e.g. the administra-
tion of ACE-inhibitors or aspirin. The possibility should
be considered, however, that many other pathways remain
unknown and counteracting them might have a more spe-
cific and intensive effect than what we have available right
now, largely on empirical grounds. Of note, most of the cur-
rently applied preventive and therapeutic approaches have
not been developed for the renal population and tested in
this patient group either.
The other applications that can be developed once the
most important culprits are known are removal strate-
gies. Hereby one might think about dialysis strategies, but
more specific approaches might include adsorption, which
should not necessarily be applied in contact with blood,
other options being plasma, ultrafiltrate or gastrointestinal
contents.
Once such therapies are developed, they should be tested
in controlled clinical trials, and in the case of a positive
result, application will conceivably lead to further improve-
ments of patient condition and survival.
Conclusions
Uraemic retention results in a complex picture of various
different compounds being accumulated in the body of pa-
tients affected by kidney failure. Those compounds in turn
modify several biochemical/biological systems normally
involved in the homeostasis and normal functioning of the
body. If these functions deteriorate, uraemic syndrome en-
sues. Many organic disturbances are part of uraemic syn-
drome, but one of the most vexing problems is the severe
cardiovascular disease that weighs heavily on the survival
and quality of life.
During the last decade, our knowledge of uraemic tox-
ins and their functional effects has been largely extended
(Figure 2). Obviously, compounds that are ‘difficult to re-
move by dialysis’, especially larger ‘middle’ molecules and
protein-bound solutes, have been related to many toxic ef-
fects, especially cardiovascular disease.
Enhancing the removal of these molecules by increasing
dialyzer pore size and possibly also by adding convection,
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has a beneficial impact on outcome. Based on this expe-
rience, our research for the future should focus on the de-
tection of new responsible compounds and/or mechanisms,
which should lead to the development of new removalmeth-
ods and pharmacological strategies blocking responsible
pathways, ultimately improving patient condition.
Conflict of interest statement. None declared.
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